Beneficial effect of Lactobacillus plantarum IS-10506 supplementation in adults with atopic dermatitis: a randomized controlled trial
| Autor: | Menul Ayu Umborowati, Nanny Herwanto, Cita Rosita Sigit Prakoeswa, Laissa Bonita, Ingrid S. Surono, Trisniartami Setyaningrum, Afif Nurul Hidayati, Abdul Karim |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty biology medicine.diagnostic_test business.industry Therapeutic effect Dermatology Atopic dermatitis medicine.disease Immunoglobulin E Placebo Gastroenterology law.invention 030207 dermatology & venereal diseases 03 medical and health sciences Probiotic 0302 clinical medicine Randomized controlled trial law Internal medicine biology.protein Medicine Outpatient clinic SCORAD business |
| Zdroj: | Journal of Dermatological Treatment. 33:1491-1498 |
| ISSN: | 1471-1753 0954-6634 |
| DOI: | 10.1080/09546634.2020.1836310 |
| Popis: | Introduction Although the therapeutic effects of probiotics in atopic dermatitis (AD) are known, the limited findings in adults are inconsistent. Lactobacillus plantarum (LP) IS-10506 was found to improve AD symptoms due to its immunomodulatory effects. Objective To assess the Scoring Atopic Dermatitis Index (SCORAD), the serum immunoglobulin E (IgE), interleukin (IL)-4, interferon-gamma (IFN-γ), forkhead box P3 (Foxp3+), and IL-17 levels in adults with mild and moderate AD after LP IS-10506 supplementation. Methods A randomized double-blind placebo-controlled trial comparing the microencapsulated probiotic (2 × 1010 CFU/day) and placebo (skim milk-Avicel) was conducted at an outpatient clinic on 30 adults with mild and moderate AD. The patients were divided into 2 groups with 15 patients each: intervention and control. Result The SCORAD score was significantly lower in the probiotic than the placebo group on the 8th week. The IL-4 and IL-17 levels were significantly lower in the probiotic than the placebo group. The IFN-γ and Foxp3+ levels were significantly higher in the probiotic than the placebo group. However, the IgE levels remained significantly unchanged. Conclusion The administration of LP IS-10506 is effective for alleviating AD symptoms in adults owing to its immunomodulatory effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|